Press Release

The Ongoing Clinical Studies and Trials for Myelodysplastic Syndrome are Expected to Provide a New Dimension to MDS Care in the Coming Years.

Myelodysplastic-Syndromes-pipeline

In spite of several approved therapies, the currently the Myelodysplastic Syndrome Therapeutics market faces high unmet medical needs. In order to provide effective therapeutics options, some of the key companies in the domain such as Astex Pharmaceuticals, Onconova Therapeutics, Celgene, Aprea Therapeutics, Celyad, and others are actively involved in developing therapies. Apart from the therapeutics front, the progress in the research and the development is also likely to strengthen the treatment approaches and quality of care against MDS in the coming years. 

DelveInsight’s Myelodysplastic Syndrome Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and pre-clinical stages of development, their launch, and how the market is expected to transform in the aftermath across the Myelodysplastic Syndrome domain.

The Myelodysplastic Syndrome Pipeline Analysis report offers a 360° view of the therapeutics landscape by development stage, product type, route of administration, molecule type, and MOA for Myelodysplastic Syndrome emerging therapies.

The pipeline report lays down the business opportunities, threats, prospective collaborations, strong competitors, and growth strategies. 

Myelodysplastic syndromes are a group of disorders that occur when the blood-forming cells in the bone marrow become abnormal as a result of which the body is unable to produce healthy blood cells. People affected with Myelodysplastic Syndrome have a high symptom burden and faces the risk of death from complications of cytopenias and AML.

The treatment’s goal of MDS is to relieve symptoms, slow the progression of the disease, avoid complications and other side effects. Current treatment approaches include systemic therapy with (intensive chemotherapy and Immune therapy), stem cell transplantation, and supportive Therapies. However, the remission or progression of the disease is high, which possess serious challenges in long term. 

Some of the key highlights from the Myelodysplastic Syndrome Pipeline report:

  • Guadecitabine (SGI-110), Rigosertib, and others are some of the key therapies in the Myelodysplastic Syndrome Pipeline, the launch of these therapies is expected to improve the treatment scenario in the coming years. 
  • On April 3, 2020, the Food and Drug Administration approved luspatercept-aamt (REBLOZYL, Celgene Corporation) for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndromes.
  • In August 2020, Keros Therapeutics initiated a study to develop candidates for the treatment of low blood cell counts or cytopenias including anemia and thrombocytopenia in patients with Myelodysplastic Syndrome (MDS) and Myelofibrosis (MF).

Request for Sample @ Myelodysplastic Syndrome Pipeline Insights and Outlook

Myelodysplastic Syndrome Pipeline Analysis: Drug Profile 

The report provides an in-depth analysis of the drug in different stages of development including detailed clinical profiles, launch date, and recent product development activities. Some of the key drugs covered in the report include:

  • KER-050: Keros Therapeutics

KER-050 is an engineered ligand trap consisting of a modified ligand-binding domain of the TGF-β receptor. It is being developed by Keros Therapeutics for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis.

  • Guadecitabine (SGI-110): Astex Pharmaceuticals

Guadecitabine (SGI-110) is a second-generation DNA methylation inhibitor. It is currently being evaluated in Phase III clinical trial in subjects with MDS or chronic myelomonocytic leukemia who have failed or relapsed after adequate prior treatment with azacitidine, decitabine, or both.

  • Rigosertib: Onconova Therapeutics

Rigosertib is a small molecule, which acts as a Ras mimetic, and binds to the Ras-binding domain (RBD) found in many Ras effector proteins, including the Raf and PI3K kinase; however, it does not interact at the ATP binding site but acts via allosteric inhibition.

  • APR-246: Aprea Therapeutics

APR-246 is the lead molecule being developed by Aprea Therapeutics. The drug has been shown to reactivate mutant p53 and thereby induce programmed cell death in human cancer cells.

Visit to know more about other Myelodysplastic Syndrome drugs pipeline

Key Pipeline Therapies along with Companies 

  • Guadecitabine (SGI-110): Astex Pharmaceuticals
  • Rigosertib: Onconova Therapeutics
  • APR-246: Aprea Therapeutics
  • CYAD-02: Celyad Oncology SA
  • CC-90009: Celgene
  • KER-050: Keros Therapeutics
  • MBG453: Novartis Pharmaceuticals
  • Luspatercept: Celgene Corporation
  • SX-682: Syntrix Biosystems, Inc.
  • ASTX030: Otsuka Pharmaceutical
  • IFN-γ (interferon gamma-1b) injection: Horizon Pharma

Myelodysplastic Syndrome Pipeline Therapeutics Assessment

  • By Product Type
    • Monotherapy
    • Combination Therapy 
  • By Stage
    • Discovery 
    • Pre-clinical
    • Phase I
    • Phase II
    • Phase III
    • Pre-registration 
  • By Route of Administration
    • Oral
    • Intravenous
    • Inhalation
    • Sub-cutaneous
  • By Molecule Type
    • Small Molecule 
    • Gene Therapy
    • Stem Cell Therapy 
  • Targets:
    • Protease
    • Immunomodulatory
    • Multiple Kinase Inhibitor
  • By Mechanism of Action
    • Immune Checkpoint Inhibitors
    • Monoclonal Antibody
    • Telomerase Inhibitor

 

Got queries? Reach out for more information @ Myelodysplastic Syndrome Drug Pipeline Assessment

Scope of the Report

  • Coverage: Global
  • Key Market Players: Astex Pharmaceuticals, Onconova Therapeutics, Celgene, Aprea Therapeutics, Celyad, Keros Therapeutics, Novartis Pharmaceuticals, Syntrix Biosystems, Otsuka Pharmaceutical, Horizon Pharma USA, and many others.
  • Key Pipeline Therapies: ASTX727 LD, ASTX727 SD, Guadecitabine (SGI-110), Rigosertib, APR-246, CYAD-02, CC-90009, KER-050, MBG453, Luspatercept, SX-682, ASTX030, and many others.

Table of Content 

1

Report Introduction

2

Myelodysplastic Syndrome 

3

Myelodysplastic Syndrome Current Treatment Patterns

4

Myelodysplastic Syndrome – DelveInsight’s Analytical Perspective

5

Therapeutic Assessment

6

Myelodysplastic Syndrome Late Stage Products (Phase-III)

7

Myelodysplastic Syndrome Mid Stage Products (Phase-II)

8

Early Stage Myelodysplastic Syndrome Products (Phase-I)

9

Myelodysplastic Syndrome Pre-clinical Products and Discovery Stage Products

10

Inactive Products

11

Dormant Products

12

Myelodysplastic Syndrome Discontinued Products

13

Myelodysplastic Syndrome Product Profiles

14

Myelodysplastic Syndrome Key Companies

15

Myelodysplastic Syndrome Key Products

16

Dormant and Discontinued Products

17

Myelodysplastic Syndrome Unmet Needs

18

Myelodysplastic Syndrome Future Perspectives

19

Myelodysplastic Syndrome Analyst Review

20

Appendix

21

Report Methodology

Know more of what’s covered in the Myelodysplastic Syndrome Pipeline Assessment report

Key Questions Answered in the Myelodysplastic Syndrome Report

  • What are the current options for Myelodysplastic Syndrome treatment?
  • How many companies are developing therapies for the treatment of Myelodysplastic Syndrome? 
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Myelodysplastic Syndrome?
  • How many Myelodysplastic Syndrome emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Myelodysplastic Syndrome?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Myelodysplastic Syndrome market? 

Request for a Webex demo @ Myelodysplastic Syndrome Drug Pipeline and get a walk-through of our report 

Related Reports:

Myelodysplastic Syndrome Market

DelveInsight’ s Myelodysplastic Syndrome Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Myelodysplastic Syndrome Market trend in the 7MM (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Myelodysplastic Syndrome Epidemiology

DelveInsight’s Myelodysplastic Syndrome – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Myelodysplastic Syndrome in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Latest Reports By DelveInsight:

Electroencephelographs (EEG) Pipeline

DelveInsight’s, “Electroencephelographs (EEG) Pipeline Insight and Competitive Landscape, 2020,” report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Electroencephelographs pipeline landscape. The report provides a detailed study of the emerging Electroencephelographs devices along with the competitive landscape to help better understand the emerging Electroencephelographs devices and also covers the present clinical development scenario and growth prospects across Electroencephelographs (EEG) market. 

US Healthcare Market Outlook

DelveInsight’s, “US Healthcare Outlook Report” report provides comprehensive insights about healthcare scenarios, regulatory policies, and reimbursement landscape in the US. The report also identifies key trends in the healthcare market and provides insights into the demographic and healthcare infrastructure of the country. Along with this the report also provides a brief look into the trends and segmentation of the pharmaceutical and medical devices market of the US.

Italy Healthcare Market Outlook

DelveInsight’s, “Italy Healthcare Outlook Report” report provides comprehensive insights about healthcare scenarios, regulatory policies, and reimbursement landscape in Italy. The report also identifies key trends in the healthcare market and provides insights into the demographic and healthcare infrastructure of the country. Along with this the report also provides a brief look into the trends and segmentation of the pharmaceutical and medical devices market of Italy.

Healthcare Blog

Get in touch with our Business executive for Competitive Intelligence Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at: LinkedIn | Facebook | Twitter

Contact Information:

Shruti Thakur
[email protected] 
+1(919)321-6187 

Add Comment

Click here to post a comment

Your email address will not be published. Required fields are marked *